



echosens

MarFlow



N·I·S NikanTebSasan

Medical Equipment Importer
In the Field of Gastroenterology & Hepatology



Multiband Ligator



Shark Tooth Forceps

Alligator Forceps



touch

FibroScan 502

POWERED BY VCTE™

NO.146 ,19 St. North Karegar Ave. Tehran. Iran
Tell:+98 21 88 33 63 16
Cell:+98 912 833 63 16
Fax:+98 21 88 00 41 01
www.ntsco.ir



Pegaferon

Cornerstone Of Chronic Hepatitis C Therapy



تحت پوشش ۹۰ درصدی بیمه های :
تامین اجتماعی، خدمات درمانی و نیروهای مسلح

WWW.Pegaferon.com
۰۲۱-۸۸۹۷۰۹۸۰

پویش دارو
Pooyesh Darou



تحت پوشش کلیه بیمه‌ها



Made in USA

Cortenema[®]
hydrocortisone retention enema

دپارتمان علمی: ۰۲۱ ۲۲۲۵۰۶۱۷
دپارتمان فروش: ۰۲۱ ۲۲۲۵۱۱۴۰
توران - بلوار میرداماد - میدان محسنی - خیابان شاه‌نظری - برج ناهید - طبقه ۱۶ - واحد ۲

اسپادانا دارو پارس
Espadana Darou Pars



Feel the difference in Iranian antiemetic drugs...

MOTiDON[®]

Domperidone

- A unique gastrokinetic and antiemetic drug¹
- A great choice in add-on therapy for GERD management²
- Very rare extrapyramidal side effects¹



IR- 0315- MTD- 1681- AD

References:

1. Ann Pharmacother. 1999; 33(4): 429-440.
2. Int J Gastroenterol. 2006; 4(2): 1-8.

abidi
SINCE 1946

Leading Innovation
Leading quality

has it all...

LANZO[®]

Lansoprazole

Abidi



- ✓ Highest number of FDA approved indications ¹
- ✓ High efficacy and rapid acid-related symptoms relief ²
- ✓ Rapid onset of action ²
- ✓ As safe as placebo ³
- ✓ Very low drug interactions ³
- ✓ No interaction with Clopidogrel based on FDA label 2012 ⁴
- ✓ Class B in pregnancy ¹



abidi | Leading Innovation
SINCE 1946 | Leading quality

IR-0215-LNZ-1631-AD

1. Drug Facts and Comparisons. St. Louis, MO: Wolters Kluwer Health, Inc; 2011. p 1975.
2. Richter Joel E, Kahrlas Peter J, Sontag Stephen J, et al. Comparing Lansoprazole and Omeprazole in Onset of Heartburn Relief: Am J Gastroenterol 2001; 96: 3089-3098.
3. Blume H, Donath F, Wanke A, et al. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Safety 2006; 29: 769-784.
4. Lansoprazole: highlight of prescribing information. FDA label 2012; Reference ID: 3193013.

نماینده انحصاری شرکت MarFlow سوئیس در ایران

N.I.S

NikanTebSasan

Medical Equipment Importer
In the Field of Gastroenterology & Hepatology

Best Price With The Best Quality



NO.146 ,19 St. North Karegar Ave. Tehran. Iran

Tell:+98 21 88 33 63 16

Cell:+98 912 833 63 16

Fax:+98 21 88 00 41 01

www.ntsco.ir

MarFlow®

MEDICAL EQUIPMENT

Not Only
Management...

It's a Better life




Nexium MUPS®
esomeprazole



ABBREVIATED PRESCRIBING INFORMATION

NEXIUM® 20 mg and 40 mg Tablets See local Prescribing Information for full details, as Prescribing Information may vary from country to country. Pharmacodynamic Properties: NEXIUM® reduces gastric acid secretion through a highly targeted mechanism of action by being a specific inhibitor of the acid pump in the parietal cell. Indications: Treatment of erosive reflux esophagitis, long-term management of patients with healed esophagitis to prevent relapse, symptomatic treatment of gastroesophageal reflux disease (GERD). Treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug (NSAID) therapy. Healing of gastric ulcers associated with non-steroidal anti-inflammatory drug (NSAID) therapy, including COX-2 selective NSAIDs. Prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug (NSAID) therapy, including COX-2 selective NSAIDs, in patients at risk. In combination with an appropriate antibacterial therapeutic regimen for the eradication of *Helicobacter pylori*, healing of *Helicobacter pylori* associated duodenal ulcer and prevention of relapse of peptic ulcers in patients with *Helicobacter pylori* associated ulcers. Prolonged treatment after IV induced prevention of rebleeding of peptic ulcers. Treatment of Zollinger Ellison Syndrome Dosage: Adults and adolescents from the age of 12 years: treatment of erosive reflux esophagitis: NEXIUM® 40 mg once daily for 4-8 weeks. Long-term management of patients with healed esophagitis to prevent relapse: NEXIUM® 20 mg once daily. Symptomatic treatment of gastro-esophageal reflux disease: NEXIUM® 20 mg once daily in patients without esophagitis. Treatment of upper gastrointestinal symptoms associated with NSAID therapy: 20 mg once daily in patients requiring NSAID therapy. Healing of gastric ulcers associated with NSAID therapy: 20 mg or 40 mg once daily for 4 to 8 weeks. Prevention of gastric and duodenal ulcers associated with NSAID therapy in patients at risk: 20 mg once daily. *Helicobacter Pylori*-associated peptic ulcer disease: Healing of *Helicobacter pylori* associated duodenal ulcer and prevention of relapse of peptic ulcers in patients with *Helicobacter pylori* associated ulcers: NEXIUM® 20 mg, amoxicillin 1g and clarithromycin 500mg, all b.i.d. for one week. Prolonged treatment after IV induced prevention of rebleeding of peptic ulcers. Treatment of Zollinger Ellison Syndrome: the recommended initial dosage is NEXIUM® 40 mg twice daily. The dosage should then be individually adjusted and treatment continues as long as clinically indicated. Based on the clinical data available, the majority of patients can be controlled on doses between 80 and 160 mg

esomeprazole daily. With doses above 80 mg daily, the dose should be divided and given twice-daily. Contraindications: known hypersensitivity to esomeprazole, substituted benzimidazoles or any other constituents of the formulation. Warnings and Precautions: In the presence of any alarm symptoms (eg, significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melena) and when gastric ulcer is suspected or present, the possibility of gastric malignancy should be excluded before treatment is initiated. Patients on long-term treatment should be kept under regular surveillance. The risk of drug interaction should be considered especially when prescribing esomeprazole in combination with antibiotics for eradication of *H. pylori* or as on demand therapy. Interactions: due to the decreased intragastric acidity, the absorption of ketoconazole and itraconazole can decrease during esomeprazole treatment. Concomitant administration of esomeprazole resulted in a 45% decrease in clearance of diazepam. Concomitant administration of esomeprazole resulted in a 13% increase in trough plasma levels of phenytoin in epileptic patients; but dose adjustments were not required in this study. In healthy volunteers, combined therapy with esomeprazole and cisapride resulted in a 32% increase in AUC and a 31% prolongation of elimination half-life but no significant increase in peak plasma levels of cisapride. Concomitant administration of 40 mg esomeprazole to warfarin treated patients showed that, despite a slight elevation in the trough plasma concentration of the less potent R-isomer of warfarin, the coagulation times were within the accepted range. However, from post marketed use cases of elevated INR of clinical significance have been reported during concomitant treatment with warfarin. Close monitoring is recommended when initiating and ending treatment with warfarin or other coumarin derivatives. Concomitant administration of esomeprazole may reduce the plasma levels of atazanavir. Concomitant administration of esomeprazole and a combined inhibitor of CYP2C19 and CYP3A4, such as voriconazole, may result in more than doubling of the esomeprazole exposure. Pregnancy and lactation: caution should be exercised when prescribing NEXIUM® to pregnant women. NEXIUM® should not be used during breast-feeding. Further information is available on request from your local AstraZeneca company. NEXIUM® is a trade mark of the AstraZeneca group. © AstraZeneca Date of preparation: January 2011

If you have a medical information request please send to "medicalinfo-emm@astrazeneca.com"
If you have a patient safety concern please send to "patientsafety-emm@astrazeneca.com"


COBEL DAROU

No.5 - 13th Bakharet Ave. Tittian - Irbid 1513813811
Tel: (+98 21) 88 70 16 00 - Fax: (+98 21) 88 38 48 77

AstraZeneca
AstraZeneca Middle East & Africa
Building 133, Road 90 North - New Cairo - Egypt
www.AstraZeneca.com

01-0414-NEX-AD-0416

Choose freedom



دارای گواهینامه بالاترین استاندارد کیفیت اروپا (EDQM) برای ماده موثره

بکارگیری فرمولاسیون منحصر به فرد در ساخت جهت محافظت کامل ماده موثره از اسید معده

مدت اثر طولانی ترو تداخل دارویی پایین تر نسبت به سایر مهار کننده های پمپ هیدروژن

بیشترین پنتوپرازول نسخه شده در اروپای مرکزی در سال ۲۰۰۹



TRADITION OF EXCELLENT QUALITY



ULTOP[®]
omeprazole
Capsules 20 mg

بکارگیری تکنولوژی منحصر بفرد در تولید پلت های مقاوم به اسید جهت محافظت کامل ماده موثره از اسید معده

اثر بخشی، کیفیت و ایمنی اثبات شده در مطالعات بالینی بر روی بیش از ۷۵۰۰۰ بیمار

بیش از ۲۰ سال حضور مداوم به عنوان دارویی با کیفیت برتر در بیش از ۲۷ کشور دنیا



ACTOVERCO

Together for a healthy future

www.actoverco.com

KRKA

توزیع سراسری توسط پخش های هجرت و البت دارو در داروخانه های سراسر کشور

RANOVER[®]
Ranitidine 150

STOP THE BURN

- ✓ High quality raw-material (UQUIFA Spain) and excipients
- ✓ Unique packaging
- ✓ Prolonged stability
- ✓ Excellent dissolution profile



رانور[®] ۱۵۰ (رانیتیدین)

- ◀ اثر بخشی سریع
- ◀ ماده اولیه با کیفیت بالا
- ◀ بسته بندی مقاوم به نور و رطوبت (Alu-Alu)

ACTOVERCO

کارخانه داروسازی اکتورکو

www.actoverco.com

توزیع توسط شرکت های پخش هجرت و الیت دارو در سراسر کشور

STRENGTH AND WISDOM ALL IN ONE

In The Past Three Years , Fromilid
Has Been Sold Over 3,000,000 Tablets In Iran



FROMILID®

Tablets 500 mg

clarithromycin

ACTOVERCO

Together for a healthy future

www.actoverco.com

KRKA

توزیع سراسری توسط پخش های هجرت و الیت دارو در داروخانه های سراسر کشور

THE RIGHT MEDICINE FOR ALLERGY RELIEF !

LETIZEN[®]

Tablets 10 mg

cetirizine

... FOR ALL SEASONS



A strong and long-lasting effect on
histamine-induced symptoms



Together for a healthy future

www.actoverco.com

توزیع توسط شرکت های پخش هجرت و ایت دارو در سراسر کشور

اطلاعیه بیمه آساکول

همکاران گرامی

احتراماً بدینوسیله به استحضار می‌رساند که طبق اعلام وزارت محترم بهداشت کلیه اشکال آساکول (قرص‌های ۴۰۰ و ۸۰۰ میلی‌گرم، شیاف ۵۰۰ میلی‌گرم و انما ۴ گرم/۱۰۰ میلی‌لیتر) تحت پوشش بیمه قرار گرفته‌اند.




Mild-moderate ulcerative colitis

ASACOLTM

mesalazine

On Target for Remission



9 OUT OF **10 ASACOL**TM patients maintain
clinical remission at 6 months⁽¹⁾

Mecolzine[®] 500

Mesalazine 500 mg

Gastro-resistant tablets

 FAES FARMA



تحت پوشش کلیه
بیمه ها



Omid Darou Salamat
www.omiddarou.com

Indications:

Treatment of inflammatory bowel disease
(ulcerative colitis and Crohn`s disease)

توزیع کننده: پخش البرز، داروگستر رازی
فروش در داروخانه های سراسر کشور